NVAX Novavax Inc.

2.41
+0.11  (+5%)
Previous Close 2.3
Open 2.27
Price To Book -7.3
Market Cap 922668801
Shares 382,850,125
Volume 10,976,382
Short Ratio
Av. Daily Volume 6,811,191

SEC filingsSee all SEC filings

  1. 8-K - Current report 181169950
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166799
  3. 8-K - Current report 181157380
  4. 8-K - Current report 181005340
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181001848

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 immunogenicity and safety data data due 1Q 2019.
NanoFlu vaccine
Influenza
Phase 2 safety and immunogenicity data released July 24, 2017 - efficacy trial to be initiated 2018.
RSV F Vaccine immunogenicity trial
Respiratory Syncytial Virus (RSV) in older adults
Phase 3 released September 15, 2016 did not demonstrate efficacy.
RSV vaccine - Resolve trial
Respiratory Syncytial Virus (RSV) in older adults
Phase 2 data released September 15, 2016.
RSV F Vaccine rollover trial
Respiratory Syncytial Virus (RSV) in older adults
Phase 3 top-line data due 1Q 2019.
RSV vaccine - prepare trial
Respiratory Syncytial Virus (RSV) in healthy pregnant women - protect infants via maternal immunization
Further Phase 2 trials planned
Seasonal Influenza Vaccine
Seasonal Flu

Latest News

  1. Today's Research Reports on Trending Tickers: Novavax and Applied Genetic Technologies
  2. 3 Top Biotech Stocks to Buy in December
  3. Here's What Pushed Novavax Stock Up 17.6% in November
  4. Novavax Announces Leadership Promotions
  5. Some of December's Most Interesting Stocks
  6. 2 Biotech Stocks Poised for Big Gains in 2019
  7. Analysis: Positioning to Benefit within Symantec, ACADIA Pharmaceuticals, Novavax, BBX Capital, Paychex, and US Foods Holding — Research Highlights Growth, Revenue, and Consolidated Results
  8. Why Novavax Is Up 60% in 2018
  9. Why Novavax Soared Today
  10. Today's Research Reports on Trending Tickers: Novavax and ACADIA Pharmaceuticals
  11. 4 Healthcare Stocks Seeing New Highs On Monday
  12. Edited Transcript of NVAX earnings conference call or presentation 7-Nov-18 9:30pm GMT
  13. Novavax Expands Leadership with Several Key Management Promotions
  14. Does Novavax Inc’s (NASDAQ:NVAX) CEO Pay Reflect Performance?
  15. What Novavax needs for success as it advances blockbuster vaccine candidates
  16. Novavax (NVAX) Reports Q3 Loss, Lags Revenue Estimates
  17. Novavax: 3Q Earnings Snapshot
  18. Novavax Reports Third Quarter 2018 Financial Results
  19. Q3 Earnings Outlook For Novavax
  20. Novavax (NVAX) Gains As Market Dips: What You Should Know

SEC Filings

  1. 8-K - Current report 181169950
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181166799
  3. 8-K - Current report 181157380
  4. 8-K - Current report 181005340
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 181001848
  6. S-8 - Securities to be offered to employees in employee benefit plans 18985416
  7. 8-K - Current report 18966693
  8. 8-K - Current report 18902797
  9. CT ORDER - Confidential treatment order 18890131
  10. 8-K - Current report 18822785